Global Nano-antibody CDMO Services 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI08257199

Publication Date:

August 11, 2025

Pages:

128

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

According to this study, the global Nano-antibody CDMO Services market size will reach US$ 1499 million by 2031.
Nano-antibody CDMO service provides biopharmaceutical companies with full-process outsourcing support for nano-antibody drugs from research and development to commercialization, covering modules such as antibody screening, humanization, expression optimization, process development, GMP pilot production, formulation development and clinical application support. Compared with traditional IgG antibodies, nano-antibodies have the advantages of small size, strong penetration, easy modification, and high expression efficiency. They are widely used in tumor immunity, inflammation, autoimmunity, imaging diagnosis and inhalation preparations. With the rapid growth of the global nano-antibody drug pipeline, CDMO service platforms that focus on this type of molecule continue to develop and become an important sub-track in antibody CDMO, with high added value and high technical barriers.
United States market for Nano-antibody CDMO Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Nano-antibody CDMO Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Nano-antibody CDMO Services is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Nano-antibody CDMO Services players cover ProBio, GenScript, Sanofi, Abzena, Pierre Fabre, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淣ano-antibody CDMO Services Industry Forecast鈥� looks at past sales and reviews total world Nano-antibody CDMO Services sales in 2024, providing a comprehensive analysis by region and market sector of projected Nano-antibody CDMO Services sales for 2025 through 2031. With Nano-antibody CDMO Services sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nano-antibody CDMO Services industry.
This Insight Report provides a comprehensive analysis of the global Nano-antibody CDMO Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Nano-antibody CDMO Services portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Nano-antibody CDMO Services market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nano-antibody CDMO Services and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nano-antibody CDMO Services.
This report presents a comprehensive overview, market shares, and growth opportunities of Nano-antibody CDMO Services market by product type, application, key players and key regions and countries.
Segmentation by Type:
Antigen Design
Gene Synthesis
Vector Construction
Others
Segmentation by Application:
Pharmaceutical Companies
Biological Laboratories
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
ProBio
GenScript
Sanofi
Abzena
Pierre Fabre
ImmunoPrecise Antibodies
PeptiFinder Biotech
Jotbody
53Biologics
Shilpa Biologicals Private
Cultiply
PolyPeptide
CordenPharma
Bachem
Yaohai Bio
Nuoanjian Biotech
BioInno Biotechnology
Bioworkshops
Abace Biotechnology
Medicilon

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Nano-antibody CDMO Services 麻豆原创 Size (2020-2031)
2.1.2 Nano-antibody CDMO Services 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Nano-antibody CDMO Services by Country/Region (2020, 2024 & 2031)
2.2 Nano-antibody CDMO Services Segment by Type
2.2.1 Antigen Design
2.2.2 Gene Synthesis
2.2.3 Vector Construction
2.2.4 Others
2.3 Nano-antibody CDMO Services 麻豆原创 Size by Type
2.3.1 Nano-antibody CDMO Services 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Nano-antibody CDMO Services 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Nano-antibody CDMO Services Segment by Application
2.4.1 Pharmaceutical Companies
2.4.2 Biological Laboratories
2.4.3 Others
2.5 Nano-antibody CDMO Services 麻豆原创 Size by Application
2.5.1 Nano-antibody CDMO Services 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Nano-antibody CDMO Services 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Nano-antibody CDMO Services 麻豆原创 Size by Player
3.1 Nano-antibody CDMO Services 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Nano-antibody CDMO Services Revenue by Player (2020-2025)
3.1.2 Global Nano-antibody CDMO Services Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Nano-antibody CDMO Services Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Nano-antibody CDMO Services by Region
4.1 Nano-antibody CDMO Services 麻豆原创 Size by Region (2020-2025)
4.2 Global Nano-antibody CDMO Services Annual Revenue by Country/Region (2020-2025)
4.3 Americas Nano-antibody CDMO Services 麻豆原创 Size Growth (2020-2025)
4.4 APAC Nano-antibody CDMO Services 麻豆原创 Size Growth (2020-2025)
4.5 Europe Nano-antibody CDMO Services 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Nano-antibody CDMO Services 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Nano-antibody CDMO Services 麻豆原创 Size by Country (2020-2025)
5.2 Americas Nano-antibody CDMO Services 麻豆原创 Size by Type (2020-2025)
5.3 Americas Nano-antibody CDMO Services 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nano-antibody CDMO Services 麻豆原创 Size by Region (2020-2025)
6.2 APAC Nano-antibody CDMO Services 麻豆原创 Size by Type (2020-2025)
6.3 APAC Nano-antibody CDMO Services 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Nano-antibody CDMO Services 麻豆原创 Size by Country (2020-2025)
7.2 Europe Nano-antibody CDMO Services 麻豆原创 Size by Type (2020-2025)
7.3 Europe Nano-antibody CDMO Services 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Nano-antibody CDMO Services by Region (2020-2025)
8.2 Middle East & Africa Nano-antibody CDMO Services 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Nano-antibody CDMO Services 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Nano-antibody CDMO Services 麻豆原创 Forecast
10.1 Global Nano-antibody CDMO Services Forecast by Region (2026-2031)
10.1.1 Global Nano-antibody CDMO Services Forecast by Region (2026-2031)
10.1.2 Americas Nano-antibody CDMO Services Forecast
10.1.3 APAC Nano-antibody CDMO Services Forecast
10.1.4 Europe Nano-antibody CDMO Services Forecast
10.1.5 Middle East & Africa Nano-antibody CDMO Services Forecast
10.2 Americas Nano-antibody CDMO Services Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Nano-antibody CDMO Services Forecast
10.2.2 Canada 麻豆原创 Nano-antibody CDMO Services Forecast
10.2.3 Mexico 麻豆原创 Nano-antibody CDMO Services Forecast
10.2.4 Brazil 麻豆原创 Nano-antibody CDMO Services Forecast
10.3 APAC Nano-antibody CDMO Services Forecast by Region (2026-2031)
10.3.1 China Nano-antibody CDMO Services 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Nano-antibody CDMO Services Forecast
10.3.3 Korea 麻豆原创 Nano-antibody CDMO Services Forecast
10.3.4 Southeast Asia 麻豆原创 Nano-antibody CDMO Services Forecast
10.3.5 India 麻豆原创 Nano-antibody CDMO Services Forecast
10.3.6 Australia 麻豆原创 Nano-antibody CDMO Services Forecast
10.4 Europe Nano-antibody CDMO Services Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Nano-antibody CDMO Services Forecast
10.4.2 France 麻豆原创 Nano-antibody CDMO Services Forecast
10.4.3 UK 麻豆原创 Nano-antibody CDMO Services Forecast
10.4.4 Italy 麻豆原创 Nano-antibody CDMO Services Forecast
10.4.5 Russia 麻豆原创 Nano-antibody CDMO Services Forecast
10.5 Middle East & Africa Nano-antibody CDMO Services Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Nano-antibody CDMO Services Forecast
10.5.2 South Africa 麻豆原创 Nano-antibody CDMO Services Forecast
10.5.3 Israel 麻豆原创 Nano-antibody CDMO Services Forecast
10.5.4 Turkey 麻豆原创 Nano-antibody CDMO Services Forecast
10.6 Global Nano-antibody CDMO Services Forecast by Type (2026-2031)
10.7 Global Nano-antibody CDMO Services Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Nano-antibody CDMO Services Forecast
11 Key Players Analysis
11.1 ProBio
11.1.1 ProBio Company Information
11.1.2 ProBio Nano-antibody CDMO Services Product Offered
11.1.3 ProBio Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 ProBio Main Business Overview
11.1.5 ProBio Latest Developments
11.2 GenScript
11.2.1 GenScript Company Information
11.2.2 GenScript Nano-antibody CDMO Services Product Offered
11.2.3 GenScript Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 GenScript Main Business Overview
11.2.5 GenScript Latest Developments
11.3 Sanofi
11.3.1 Sanofi Company Information
11.3.2 Sanofi Nano-antibody CDMO Services Product Offered
11.3.3 Sanofi Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Sanofi Main Business Overview
11.3.5 Sanofi Latest Developments
11.4 Abzena
11.4.1 Abzena Company Information
11.4.2 Abzena Nano-antibody CDMO Services Product Offered
11.4.3 Abzena Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Abzena Main Business Overview
11.4.5 Abzena Latest Developments
11.5 Pierre Fabre
11.5.1 Pierre Fabre Company Information
11.5.2 Pierre Fabre Nano-antibody CDMO Services Product Offered
11.5.3 Pierre Fabre Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Pierre Fabre Main Business Overview
11.5.5 Pierre Fabre Latest Developments
11.6 ImmunoPrecise Antibodies
11.6.1 ImmunoPrecise Antibodies Company Information
11.6.2 ImmunoPrecise Antibodies Nano-antibody CDMO Services Product Offered
11.6.3 ImmunoPrecise Antibodies Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 ImmunoPrecise Antibodies Main Business Overview
11.6.5 ImmunoPrecise Antibodies Latest Developments
11.7 PeptiFinder Biotech
11.7.1 PeptiFinder Biotech Company Information
11.7.2 PeptiFinder Biotech Nano-antibody CDMO Services Product Offered
11.7.3 PeptiFinder Biotech Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 PeptiFinder Biotech Main Business Overview
11.7.5 PeptiFinder Biotech Latest Developments
11.8 Jotbody
11.8.1 Jotbody Company Information
11.8.2 Jotbody Nano-antibody CDMO Services Product Offered
11.8.3 Jotbody Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Jotbody Main Business Overview
11.8.5 Jotbody Latest Developments
11.9 53Biologics
11.9.1 53Biologics Company Information
11.9.2 53Biologics Nano-antibody CDMO Services Product Offered
11.9.3 53Biologics Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 53Biologics Main Business Overview
11.9.5 53Biologics Latest Developments
11.10 Shilpa Biologicals Private
11.10.1 Shilpa Biologicals Private Company Information
11.10.2 Shilpa Biologicals Private Nano-antibody CDMO Services Product Offered
11.10.3 Shilpa Biologicals Private Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Shilpa Biologicals Private Main Business Overview
11.10.5 Shilpa Biologicals Private Latest Developments
11.11 Cultiply
11.11.1 Cultiply Company Information
11.11.2 Cultiply Nano-antibody CDMO Services Product Offered
11.11.3 Cultiply Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Cultiply Main Business Overview
11.11.5 Cultiply Latest Developments
11.12 PolyPeptide
11.12.1 PolyPeptide Company Information
11.12.2 PolyPeptide Nano-antibody CDMO Services Product Offered
11.12.3 PolyPeptide Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 PolyPeptide Main Business Overview
11.12.5 PolyPeptide Latest Developments
11.13 CordenPharma
11.13.1 CordenPharma Company Information
11.13.2 CordenPharma Nano-antibody CDMO Services Product Offered
11.13.3 CordenPharma Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 CordenPharma Main Business Overview
11.13.5 CordenPharma Latest Developments
11.14 Bachem
11.14.1 Bachem Company Information
11.14.2 Bachem Nano-antibody CDMO Services Product Offered
11.14.3 Bachem Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Bachem Main Business Overview
11.14.5 Bachem Latest Developments
11.15 Yaohai Bio
11.15.1 Yaohai Bio Company Information
11.15.2 Yaohai Bio Nano-antibody CDMO Services Product Offered
11.15.3 Yaohai Bio Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Yaohai Bio Main Business Overview
11.15.5 Yaohai Bio Latest Developments
11.16 Nuoanjian Biotech
11.16.1 Nuoanjian Biotech Company Information
11.16.2 Nuoanjian Biotech Nano-antibody CDMO Services Product Offered
11.16.3 Nuoanjian Biotech Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Nuoanjian Biotech Main Business Overview
11.16.5 Nuoanjian Biotech Latest Developments
11.17 BioInno Biotechnology
11.17.1 BioInno Biotechnology Company Information
11.17.2 BioInno Biotechnology Nano-antibody CDMO Services Product Offered
11.17.3 BioInno Biotechnology Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 BioInno Biotechnology Main Business Overview
11.17.5 BioInno Biotechnology Latest Developments
11.18 Bioworkshops
11.18.1 Bioworkshops Company Information
11.18.2 Bioworkshops Nano-antibody CDMO Services Product Offered
11.18.3 Bioworkshops Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.18.4 Bioworkshops Main Business Overview
11.18.5 Bioworkshops Latest Developments
11.19 Abace Biotechnology
11.19.1 Abace Biotechnology Company Information
11.19.2 Abace Biotechnology Nano-antibody CDMO Services Product Offered
11.19.3 Abace Biotechnology Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.19.4 Abace Biotechnology Main Business Overview
11.19.5 Abace Biotechnology Latest Developments
11.20 Medicilon
11.20.1 Medicilon Company Information
11.20.2 Medicilon Nano-antibody CDMO Services Product Offered
11.20.3 Medicilon Nano-antibody CDMO Services Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.20.4 Medicilon Main Business Overview
11.20.5 Medicilon Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.